{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"81","upperLimit":"100","value":"92"},{"groupId":"OG001","lowerLimit":"45","upperLimit":"100","value":"71"}]}],"title":"At 3 months after enrollment"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"70","upperLimit":"100","value":"83"},{"groupId":"OG001","lowerLimit":"45","upperLimit":"100","value":"71"}]}],"title":"At 6 months after enrollment"}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"25"}],"units":"Participants"}],"description":"Survival without measurable progression of lymphoma estimated according to the Kaplan-Meier method","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients received previous treatment. Patients enrolled in the trial received dexamethasone IV and rituximab IV once weekly. Treatment continues for 4 weeks in the absence of disease progression or unacceptable toxicity.\n\npharmacological study: Correlative studies\n\nrituximab: Given IV\n\ndexamethasone: Given IV\n\nlaboratory biomarker analysis: Correlative studies","id":"OG000","title":"Previous Treatment"},{"description":"Patients received no previous treatment. Patients enrolled in the trial received dexamethasone IV and rituximab IV once weekly. Treatment continues for 4 weeks in the absence of disease progression or unacceptable toxicity.\n\npharmacological study: Correlative studies\n\nrituximab: Given IV\n\ndexamethasone: Given IV\n\nlaboratory biomarker analysis: Correlative studies","id":"OG001","title":"No Previous Treatment"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"At 3 and 6 months after enrollment","title":"Progression-free Survival","type":"PRIMARY","unitOfMeasure":"Kaplan-Meier estimated % of patients"}